

CONTENTS

List of Tables	i
List of Figures	iii
Abbreviations & symbols	ix
Preface	xi

Chapters	Page No.
1 Introduction.....	1
2 Literature review.....	9
2.1 Structure of skin.....	9
2.2 Wounds.....	10
2.3 Wound healing.....	13
2.4 Wounds healing impairment in diabetic patient.....	15
2.4.1 Background.....	15
2.4.2 Healing impairment in diabetic.....	16
2.4.3 Fungal infection in diabetic.....	17
2.5 Conventional treatment of fungal wounds.....	18
2.6 Use of biopolymer based nanofiber dressings.....	18
2.6.1 Preparation of biopolymer nanofibers.....	21
2.6.2 Factors affecting nanofiber preparations.....	23
2.7 Polymer profiles.....	29
2.7.1 Polycaprolactone.....	29
2.7.2 Gelatin.....	31
2.7.3 Polyvinyl alcohol.....	32
2.7.4 Chitosan.....	34
2.8 Drug profile.....	36
2.8.1 Luliconazole.....	36
2.8.2 Naringenin.....	38
3 Materials and analytical method.....	43
3.1 Materials.....	43
3.2 Instruments.....	45
3.3 Software.....	47

3.4	Analytical method	47
3.4.1	Development of HPLC method for the estimation of luliconazole and naringenin.	47
3.4.2	Analytical method validation.....	48
3.4.3	Results.....	49
4	Formulation and characterization of polyvinyl alcohol/chitosan composite nanofiber co-loaded with silver nanoparticle & luliconazole encapsulated poly lactic-co-glycolic acid nanoparticle for treatment of <i>Candida</i> infected diabetic wounds.....	57
4.1	Plan of study.....	57
4.2	Materials.....	58
4.3	Method	58
4.3.1	Preparation of nanoparticles	58
4.3.2	Preparation of nanoparticles loaded nanofibers	59
4.3.3	Morphological characterization	60
4.3.4	Solid state characterization	61
4.3.5	<i>In-vitro</i> characterization.....	61
4.3.6	<i>In-vivo</i> bioimaging analysis	63
4.3.7	Antifungal & antibiofilm activity	64
4.3.8	Hemocompatibility study.....	64
4.3.9	<i>In-vitro</i> cytocompatibility Study.....	65
4.3.10	<i>In vivo</i> wound healing activity.....	66
4.3.11	Histopathological study	66
4.3.12	Laser doppler study.....	67
4.3.13	Statistical analysis.....	67
4.4	Results.....	67
4.4.1	Preparation of PVA/CH-AGNP-LZNP NF	67
4.4.2	Morphological characterization	68
4.4.3	Solid-state characterization.....	70
4.4.4	<i>In-vitro</i> characterization results	75
4.4.5	<i>In-vivo</i> bio-imaging analysis.....	80
4.4.6	Antifungal and antibiofilm activity.....	81
4.4.7	Hemocompatibility study.....	84
4.4.8	<i>In-vitro</i> cytocompatibility and cell viability activity	84
4.4.9	<i>In-vivo</i> wound healing activity.....	86
4.4.10	Histological study	87
4.4.11	Laser doppler study.....	88

4.5	Discussion & conclusions	90
5	Fabrication of gelatin coated polycaprolactone nanofiber scaffolds co-loaded with luliconazole and naringenin for treatment of <i>candida</i> infected diabetic wounds	95
5.1	Plan of study.....	95
5.2	Materials.....	96
5.3	Methods.....	96
5.3.1	Optimization of gelatin coated PCL nanofiber scaffolds.....	96
5.3.2	Morphological characterization	97
5.3.3	Solid state characterization	98
5.3.4	Water contact angle & surface pH study	99
5.3.5	Water absorption capacity and vapour transmission rate	99
5.3.6	Entrapment efficiency and drug content uniformity	100
5.3.7	Drug release profile.....	100
5.3.8	<i>In-vivo</i> release analysis	101
5.3.9	Antifungal and antibiofilm activity.....	101
5.3.10	Hemocompatibility study.....	102
5.3.11	<i>In-vitro</i> cytocompatibility study	102
5.3.12	<i>In-vivo</i> wound healing activity.....	103
5.3.13	Histopathological study	104
5.3.14	Laser doppler study.....	104
5.3.15	Statistical analysis.....	105
5.4	Results	105
5.4.1	Morphological characterization	105
5.4.2	Solid state characterization	107
5.4.3	FTIR Study.....	107
5.4.4	Water contact angle and surface pH study.....	111
5.4.5	Water absorption capacity and water vapour transmission rate (WVT)....	111
5.4.6	Entrapment efficiency and drug content uniformity	113
5.4.7	Drug release study.....	113
5.4.8	<i>In-vivo</i> imaging study	114
5.4.9	Antifungal and antibiofilm activity.....	116
5.4.10	Hemocompatibility study.....	117
5.4.11	<i>In-vitro</i> cytocompatibility study	117
5.4.12	<i>In vivo</i> wound healing study	119
5.4.13	Histopathological Study.....	121

5.4.14	Laser Doppler study	122
5.5	Discussion & conclusions	124
6	Comparative evaluation of GL/PCL-LTZ-NAR and PVA/CH-AgNP-LZNP nanofiber with market cream Luligel™ for treatment of <i>Candida</i> infected diabetic wounds.	129
6.1	Plan of study.....	129
6.2	Materials.....	129
6.3	Methods.....	129
6.3.1	<i>In-vivo</i> wound healing study	129
6.3.2	Histopathological study	130
6.3.3	Laser doppler study.....	130
6.4	Results	130
6.4.1	<i>In-vivo</i> wound healing study.....	130
6.4.2	Histopathological study	132
6.4.3	Laser doppler study.....	133
6.5	Discussion and conclusions.....	135
7	Summary and conclusions	139
7.1	Summary	139
7.2	Conclusions	141
8	References.....	145

List of Tables

Table 2.1 Literature survey reporting the application of nanofibers in wound healing.....	20
Table 2.2 Different type of nanofiber and their applications.....	22
Table 2.3 Different literature work published across the globe for the luliconazole.....	38
Table 2.4 Literature work published across the globe related to naringenin and its use in wound healing.....	40
Table 3.1 List of materials used for the study.....	43
Table 3.2 List of Instruments used for the study	45
Table 3.3 List of Softwares used for the study	47
Table 3.4 Regression parameter from calibrations curve	52
Table 3.5 Accuracy and precision of the developed method.....	52
Table 3.6 Limit of detection and Limit of Quantification of luliconazole and naringenin	54
Table 4.1 Representation of the different proportion of drug and polymer used for fabrication of nanofibers.....	60
Table 4.2 Entrapment efficiency and Mean diameter of prepared nanoparticles and nanofiber mats.....	79
Table 5.1 Schematic representation of Polymer and Solvent ratio for nanofiber preparation.....	97
Table 5.2 Tabular representation of median diameter and average diameter of prepared nanofiber mats.....	107
Table 5.3 Entrapment efficiency of luliconazole and naringenin by different nanofibers.....	113

List of Figures

Figure 2.1 Structure of the skin	10
Figure 2.2 Phase of wound healing	14
Figure 2.3 Wound impairment in diabetic mellitus	17
Figure 2.4 Formation of various type of jets with flow rates	28
Figure 2.5 Molecular Structure of Polycaprolactone.....	29
Figure 2.6 Molecular Structure of gelatin.....	31
Figure 2.7 Molecular Structure of Polyvinyl Alcohol.....	34
Figure 2.8 Molecular Structure of Chitosan	35
Figure 2.9 Molecular structure of luliconazole.....	37
Figure 2.10 Molecular structure of naringenin.....	39
Figure 3.1 Calibration curve of luliconazole	50
Figure 3.2 Calibration curve of Naringenin.....	50
Figure 3.3 Calibration curve of Luliconazole in combination with naringenin.....	51
Figure 3.4 Calibration curve of Naringenin in combination with luliconazole	51
Figure 3.5 Luliconazole chromatogram	53
Figure 3.6 Naringenin chromatogram.....	53
Figure 3.7 Luliconazole chromatogram in combination with naringenin.....	53
Figure 3.8 Naringenin chromatogram in combination with luliconazole	53
Figure 4.1 Transmission electron microscopy and scanning electron microscopy image of AgNP and LZNP.....	68
Figure 4.2 Transmission electron microscopy and scanning electron microscopy images of optimized PVA/CH-AgNP-LZNP nanofiber.....	69

Figure 4.3 Scanning electron microscopy images of the PVA/CH NF, PVA/CH-AgNP NF, PVA/CH-LZNP NF and PVA/CH-AgNP-LZNP NF.	70
Figure 4.4 FT-IR spectra of drug, polymer and prepared nanofiber.....	72
Figure 4.5 XRD spectra of drug, polymer and prepared nanofiber.	73
Figure 4.6 DSC thermogram of drug, polymer and prepared nanofiber.....	74
Figure 4.7 (A) Graphical representation of the PVA/CH-AgNP-LZNP NF water contact angle with respect to Time (Sec); (B) Contact angle of PVA/CH-AgNP-LZNP NF at different time points (sec); (C) Bar diagram for water contact angle image of PVA NF, PVA/CH NF, PVA/CH-AgNP NF, PVA/CH-LZNP NF and PVA/CH-AgNP-LZNP NF. (D) Surface pH of PVA NF, PVA/CH NF, PVA/CH-AgNP NF, PVA/CH-LZNP NF and PVA/CH-AgNP-LZNP NF nanofibers (In all graphs vertical bars represent standard deviation (n=3), 'ns' represent non significance difference, * represent p value <0.05, and ** represent p value <0.01).....	76
Figure 4.8 Bar graphs representing % Water uptake capacity (A) & Water vapour transmission rate (B) of PVA NF, PVA/CH NF, PVA/CH-AgNP NF, PVA/CH-LZNP NF and PVA/CH-AgNP-LZNP NF (In both graph vertical bars represent standard deviation (n=3), * represent p value <0.05, and ** represent p value <0.01 and *** represent p value < 0.001).....	78
Figure 4.9 Drug release kinetic modelling of luliconazole from LZNP and PVA/CH-AgNP-LZNP NF formulation.....	80
Figure 4.10 (A) In-vitro drug release of LZ from LZNP and PVA/CH-AgNP-LZNP NF; (B) Graphical representation of fluorescence count vs time (hr) response of DID-dye; and (C) <i>In-vivo</i> imaging study showing the release of encapsulated DID dye from nanofiber at wound site (In all figures vertical bar represent standard deviation (n=3))......	81

Figure 4.11 (A) Inhibition zone images of PVA/CH NF (1), PVA/CH-AgNP-LZNP NF (2) & PVA/CH-AgNP NF (3) showing antifungal activity against *C.albicans*, *C.auris*, *C.krusei*, *C.parapsilosis*, *C.tropicalis*; (B) Graphical representation of zone of inhibition (mm) values of PVA/CH-AgNP, PVA/CH-LZNP and PVA/CH-AgNP-LZNP NF (In graph vertical bars represent standard deviation (n=3), ‘ns’ represent non significant, and **** represent p value < 0.0001).....82

Figure 4.12 (A) Bar graph of MTT assay showing antibiofilm activity of Control, PVA/CH NF and PVA/CH-AgNP-LZNP NF against *C.albicans* and *C.tropicalis*; (B) SEM images (500X) showing *C.albicans* and *C.tropicalis* after PVA/CH NF and PVA/CH-AgNP-LZNP NF treatment (In graph vertical bars represent standard deviation (n=3), ‘ns’ represent non significant, ** represent p value < 0.01 and *** represent p value < 0.001).83

Figure 4.13 (A) Phase contract microscopy images of PVA/CH NF and PVA/CH-AgNP-LZNP NF (White bar represent 400µm); (B) Bar graph showing % cell viability of Control, PVA/CH NF and PVA/CH-AgNP-LZNP NF groups after 24, 48 and 72hr (In graph vertical bars represent standard deviation (n=3) and ‘ns’ represent non significant difference).....85

Figure 4.14 Wound image of *In-vivo* wound closure study showing wounds healing in PVA/CH NF, PVA/CH-AgNP NF, PVA-CH-LZNP NF, and PVA/CH-AGNP-LZNP NF treatment groups at Day 0, 4, 11 and 18; (B) Bar graph showing % wound area over time graph (In graph vertical bars represent standard deviation (n=3), * represent p value < 0.05, ** represent p value < 0.01 and *** represent p value < 0.001).87

Figure 4.15 Histological study result of different treatment groups at Day 11 and 18 of study.....88

Figure 4.16 (A) Laser doppler study of different treatment groups showing blood flow around wound area; (B) Bar graph of ROI values obtained from laser doppler in different

treatment groups on day 11 & 18 (In graph vertical bars represent standard deviation (n=3), ** represent p value < 0.01, *** represent p value < 0.001, and **** represent p value < 0.0001).90

Figure 5.1 (A) Transmission electron image of prepared nanofiber; (B) Confocal Image of GL-PCL-Coumarin-6 loaded nanofiber; Scanning electron Image of GL-PCL (C) & GL-PCL-LTZ/NAR respectively (D); (E&F) 2D & 3D AFM image of GL-PCL-LTZ/NAR. 106

Figure 5.2 FTIR spectra of drugs (luliconazole and naringenin), polymer and prepared nanofibers with luliconazole (LTZ), naringenin (NAR), polycaprolactone (PCL), gelatin (GL), gelatin coated PCL nanofiber (GL-PCL), LTZ & NAR loaded gelatin coated PCL nanofiber (GL-PCL-LTZ/NAR). 108

Figure 5.3 XRD spectra of drugs, polymer and prepared nanofibers with luliconazole (LTZ), naringenin (NAR), polycaprolactone (PCL), gelatin (GL), gelatin coated PCL nanofiber (GL-PCL), and LTZ & NAR loaded gelatin coated PCL nanofiber (GL-PCL-LTZ/NAR). 109

Figure 5.4 Differential scanning calorimetry thermogram of drugs, polymer, and formulation with luliconazole (LTZ), naringenin (NAR), polycaprolactone (PCL), gelatin (GL), gelatin coated PCL nanofiber (GL-PCL), LTZ & NAR loaded gelatin coated PCL nanofiber (GL-PCL-LTZ/NAR). 110

Figure 5.5 Contact angle image of (A) PCL nanofiber, (B) GL nanofiber, (C) GL-PCL Nanofiber, (D) GL-PCL-LTZ/NAR nanofiber; (E) Contact angle of different formulations; (F) Surface pH graph of different formulations (In all graphs vertical bars represent standard deviations (n=3), 'ns' represent non significant, ** represent p value < 0.01 and *** represent p value < 0.001). 111

Figure 5.6 (A) % water uptake capacity, (B) Water vapour transmission rate of different nanofibers (In both graph vertical bars represent standard deviation (n=3), * represent p value <0.05, and ** represent p value <0.01 and *** represent p value < 0.001)..... 112

Figure 5.7 Drug release kinetic modelling of luliconazole and naringenin from GL/PCL-LTZ-NAR NF formulation 114

Figure 5.8 (A) Drug release profile of LTZ & NAR from GL-PCL-LTZ/NAR; (B) Fluorescence count vs Time graph of *In-vivo* release study (C) *In-vivo* release of DiD dye from GL-PCL nanofiber (vertical bars in all graphs represent standard deviations (n=3)). 115

Figure 5.9 Antifungal activity of GL-PCL, GL-PCL-LTZ, GL-PCL-LTZ/NAR against (A) *C.albicans*; (B) *C.auri*; (C) *C.parapsilosis*; (D) *C.tropicalis*; (E) *C.krusei*; and (F) Zone of inhibition bar graph GL-PCL-LTZ and GL-PCL-LTZ/NAR (vertical bars in graph represent standard deviations (n=3))..... 116

Figure 5.10 (A) SEM image of GL-PCL, GL-PCL-LTZ/NAR showing activity against *C.albicans* and *C.tropicalis* at 500X; (B) Antibiofilm activity (MTT assay) of GL-PCL, GL-PCL-LTZ & GL-PCL-LTZ/NAR against *C.albicans* and *C.tropicalis* (Vertical bars in graph represent standard deviations (n=3), ‘ns’ represent non significant and *** represent p value < 0.001).. 117

Figure 5.11 Phase contrast microscope image (Up) of HaCaT cytocompatibility study for GL-PCL and GL-PCL-LTZ/NAR nanofiber in 24, 48 and 72 hr (white scale bar = 400µm); Bar graph (down) representing % Cell viability of different nanofiber groups showing non-significant difference (p value>0.05) between Control and GL-PCL-LTZ/NAR & GL-PCL nanofiber (Vertical bars in graph represent standard deviations (n=3) and ‘ns’ represent non significant). 118

Figure 5.12 (A) Wound Closure study images of Gauze treated, GL-PCL nanofiber, and GL-PCL-NAR, GL-PCL-LTZ, and GL-PCL-LTZ/NAR group; (B) Quantitative data indicating % wound area of different treatment groups (Vertical bars in graph represent standard deviations (n=3), * represent p value < 0.05, ** represent p value < 0.01 and *** represent p value < 0.001)..... 120

Figure 5.13 Histological H&E stained image of Gauze treated, GL-PCL, GL-PCL-NAR and GL-PCL-LTZ & GL-PCL-LTZ/NAR on day 12 and 21 of study 121

Figure 5.14 (A) Laser Doppler images (B) Graphical representation of the quantitative values obtain from laser doppler study (Vertical bars in graph represent standard deviations (n=3), ‘ns’ represent non significant, * represent p value < 0.05, ** represent p value < 0.01 and *** represent p value < 0.001). 123

Figure 6.1 (A) Wound closure study image on different time points (B) Bar graph showing % wound area on Day 11 and Day 18 (Vertical bars in graph represent standard deviations (n=3), * represent p value < 0.05, ** represent p value < 0.01 and *** represent p value < 0.001). 131

Figure 6.2 H&E histological data of different treatment groups on day 11 and 18..... 133

Figure 6.3 (A) Laser doppler image of different treatments; (B) Bar graph showing Blood flow around wound area in different treatment groups (Vertical bars in graph represent standard deviations (n=3), ** represent p value < 0.01, *** represent p value < 0.001).134